Get the Stockscreener App
4.70
11.32%
-0.60
After Hours:
4.67
-0.03
-0.64%
Genprex Inc stock is traded at $4.70, with a volume of 190.68K.
It is down -11.32% in the last 24 hours and down -51.02% over the past month.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
See More
Previous Close:
$5.30
Open:
$5.02
24h Volume:
190.68K
Relative Volume:
0.28
Market Cap:
$11.33M
Revenue:
-
Net Income/Loss:
$-22.71M
P/E Ratio:
-0.4014
EPS:
-11.71
Net Cash Flow:
$-18.24M
1W Performance:
-32.76%
1M Performance:
-51.02%
6M Performance:
-67.59%
1Y Performance:
-95.35%
1-Day Range:
$4.6231
$5.1799
1-Week Range:
$4.6231
$7.19
52-Week Range:
$4.6231
$117.50
Genprex Inc Stock (GNPX) Company Profile
Name
Genprex Inc
Sector
Industry
Phone
512-537-7997
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
4.70 | 11.33M | 0 | -22.71M | -18.24M | -11.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-21 | Initiated | National Securities | Buy |
| Apr-29-19 | Initiated | Noble Capital Markets | Outperform |
Genprex Inc Stock (GNPX) Latest News
Genprex (GNPX) Receives European Patent Intent for Cancer Gene T - GuruFocus
Genprex gets EU nod to grant patent for Reqorsa and PD-1 antibody combo to treat cancer - MarketScreener
Genprex Secures European Patent for Reqorsa® Therapy - TipRanks
Genprex to receive European patent for cancer gene therapy combination - Investing.com
Genprex Announces European Patent Intent for Reqorsa® Gene Therapy - TradingView
Is Genprex Inc. stock safe for conservative investors2025 Bull vs Bear & Verified Entry Point Detection - newser.com
Genprex (NASDAQ: GNPX) gets EPO intent to grant patent for REQORSA+PD-1 in cancer - Stock Titan
Why Genprex Inc. stock remains a top recommendationEarnings Beat & AI Enhanced Trading Alerts - newser.com
Can Genprex Inc. (2DE0) stock stage a strong rebound this quarterMarket Sentiment Review & Long-Term Safe Return Strategies - newser.com
Analyzing drawdowns of Genprex Inc. with statistical toolsJuly 2025 Catalysts & Long-Term Capital Growth Strategies - newser.com
Can Genprex Inc. (2DE0) stock reach $200 price target2025 Retail Activity & Safe Entry Point Alerts - newser.com
Will Genprex Inc. stock deliver consistent dividendsPortfolio Gains Summary & Low Risk High Win Rate Picks - newser.com
Can technical indicators confirm Genprex Inc.’s reversalEarnings Overview Report & AI Forecasted Entry and Exit Points - newser.com
Why Genprex Inc. stock remains undervalued2025 Key Lessons & Weekly Breakout Stock Alerts - newser.com
Genprex Inc. stock retracement – recovery analysis2025 Top Gainers & Smart Allocation Stock Tips - newser.com
What technical models suggest about Genprex Inc.’s comebackJuly 2025 Review & High Conviction Investment Ideas - newser.com
How Genprex Inc. stock responds to policy changes2025 Big Picture & Low Risk Entry Point Tips - newser.com
Why Genprex Inc. stock is popular among millennialsMarket Weekly Review & Long-Term Safe Investment Plans - newser.com
How to integrate Genprex Inc. into portfolio analysis toolsPortfolio Update Report & Verified Chart Pattern Signals - newser.com
What indicators show strength in Genprex Inc.2025 Market Overview & Daily Risk Controlled Trade Plans - newser.com
Can Genprex Inc. (2DE0) stock sustain margin levels2025 Analyst Calls & Growth Focused Entry Reports - newser.com
Why analysts recommend Genprex Inc. (2DE0) stock2025 Technical Patterns & Safe Capital Preservation Plans - newser.com
Tools to monitor Genprex Inc. recovery probability2025 Volatility Report & Safe Capital Preservation Plans - newser.com
Backtesting results for Genprex Inc. trading strategiesWeekly Stock Analysis & Short-Term Trading Alerts - newser.com
Will Genprex Inc. stock reach Wall Street targetsEarnings Overview Summary & AI Enhanced Trade Execution Alerts - newser.com
Is Genprex Inc. stock ready for a breakout2025 Price Targets & Fast Entry High Yield Stock Tips - newser.com
How institutional ownership impacts Genprex Inc. stockJuly 2025 Catalysts & Free High Accuracy Swing Entry Alerts - newser.com
How Genprex Inc. (2DE0) stock reacts to Fed tightening2025 Geopolitical Influence & Daily Risk Controlled Trade Plans - newser.com
Genprex Inc Stock (GNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):